Comparative analysis of dosimetric parameters of three different radiation techniques for patients with Graves’ ophthalmopathy treated with retro-orbital irradiation

Radiation Oncology

Dora LW Kwong²  Gordon KH Au²  To Wai Leung²  Mai Yee Luk²  Cheuk Wai Choi¹  Sherry CY Ng²  Victor HF Lee² 

[1] Department of Community Medicine, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 7 Sassoon Road, Hong Kong, Hong Kong;Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 1/F, Professorial Block, Queen Mary Hospital, 102 Pokfulam Road, Pokfulam, Hong Kong

关键词: Retro-orbital irradiation;    Graves’ ophthalmopathy;    Intensity-modulated radiation therapy;   

Others  :  1155014
DOI  :  10.1186/1748-717X-7-199

 received in 2012-04-22, accepted in 2012-11-10,  发布年份 2012

【 摘 要 】

Background

We would like to investigate the if IMRT produced better target coverage and dose sparing to adjacent normal structures as compared with 3-dimensional conformal radiotherapy (3DCRT) and lateral opposing fields (LOF) for patients with Graves’ ophthalmopathy treated with retro-orbital irradiation.

Methods

Ten consecutive patients diagnosed with Graves’ ophthalmopathy were prospectively recruited into this study. An individual IMRT, 3DCRT and LOF plan was created for each patient. Conformity index (CI), homogeneity index (HI) and other dosimetric parameters of the targets and organs-at-risk (OAR) generated by IMRT were compared with the other two techniques.

Results

Mann–Whitney U test demonstrated that CI generated by IMRT was superior to that produced by 3DCRT and LOF (p=0.005 for both respectively). Similarly HI with IMRT was proven better than 3DCRT (p=0.007) and LOF (p=0.005). IMRT gave rise to better dose sparing to some OARs including globes, lenses and optic nerves as compared with 3DCRT but not with LOF.

Conclusions

IMRT, as compared with 3DCRT and LOF, was found to have a better target coverage, conformity and homogeneity and dose sparing to some surrounding structures, despite a slight increase but clinically negligible dose to other structures. Dosimetrically it might be a preferred treatment technique and a longer follow up is warranted to establish its role in routine clinical use.

【 授权许可】

   
2012 Lee et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Burch HB, Wartofsky L: Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993, 14:747-793.
• [2]Bahn RS, Heufelder AE: Pathogenesis of graves’ ophathlmopathy. N Eng J Med 1993, 329:1468-1474.
• [3]Prummel MF, Mourits MP, Blank L, et al.: Randomized double-blind trial of prednisone versus radiotherapy in graves’ ophthalmopathy. Lancet 1993, 342:949-954.
• [4]Trokel S, Kazin M, Moore S: Orbital fat removal. Decompression for graves’ orbitopathy. Ophthalmol 1993, 100:674-682.
• [5]Hallin ES, Feldon SE, Lutrell J: Graves’ ophthalmopathy: effect of transantral orbital decompression on optic neuropathy. J Ophthalmol 1988, 72:683-687.
• [6]Goyal S, Cohler A, Camporeale J, et al.: Intensity-modulated radiation therapy for orbital lymphoma. Radiat Med 2008, 26(10):573-581.
• [7]Chao KS, Deasy JO, Markman J, et al.: A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 2001, 49:907-916.
• [8]Eisbruch A, Ship JA, Dawson LA, et al.: Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head-and-neck cancer. World J Surg 2003, 27:832-837.
• [9]Nutting CM, Morden JP, Harrington KJ, et al.: Parotid- sparing intensity modulated versus conventional radiotherapy in head-and-neck cancer (PARSPORT): a phase 3 multicentre randomized controlled trial. Lancet Oncol 2011, 12:127-136.
• [10]Eisbruch A, Schwartz M, Rasch C, et al.: Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 2004, 60:1425-1439.
• [11]Al-Wassia R, Dal Pra A, Shun K, et al.: Stereotactic fractionated radiotherapy in the treatment of juxtapapillary choroidal melanoma: the McGill university experience. Int J Radiat Oncol Biol Phys 2011, 81(4):e455-e462.
• [12]Hirschbein MJ, Collins S, Jean WC, et al.: Treatment of intra-orbital lesions using the accuray CyberKnife system. Orbit 2008, 27(2):97-105.
• [13]Ulmer W, Pyyry J, Kaissl W: A 3D photon superposition/convolution algorithm and its foundation on results of Monte Carlo calculations. Phys Med Biol 2005, 50:1767-1790.
• [14]Bragg CM, Wingate K, Conway J: Clinical implications of the anisotropic analytical algorithm for IMRT treatment planning and verification. Radiother Oncol 2008, 86(2):276-284.
• [15]ICRU: Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50). Bethesda, MD: International Commission of Radiation Units and Measurements: ICRU 62; 1999.
• [16]Paddick I: A simple scoring ratio to index the conformity of plans. J Neurosurg 2000, 93(Suppl. 3):219-222.
• [17]Sheng K, Molloy JA, Larner JM, Read PW: A dosimetric comparison of non-coplanar IMRT versus Helical Tomotherapy for nasal cavity and paranasal sinus cancer. Radiother Oncol 2007, 82:174-178.
• [18]Wang X, Zhang X, Dong L, et al.: Effectiveness of noncoplanar IMRT planning using a parallelized multiresolution beam angle optimization method for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys 2005, 63:594-601.
• [19]Niemierko A: Radiobiological models of tissue response to radiation in treatment planning systems. Tumori 1998, 84(2):140-143.
• [20]Niemierko A: Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys 1997, 24(1):103-110.
• [21]Emami B, Lyman J, Brown A, et al.: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991, 21(1):109-122.
• [22]Bartalena L, Marcocci C, Tanda ML, et al.: Cigarette smoking and treatment outcomes in graves ophthalmopathy. Ann Intern Med 1998, 129(8):632-635.
• [23]Ohtsuka K, Sato A, Kawaguchi S, et al.: Effect of pulse steroid therapy with and without orbital radiotherapy on graves’ ophthalmopathy. Am J Ophthalmol 2003, 135(3):285-290.
• [24]Gorman CA, Garrity JA, Fatourechi V, et al.: The aftermath of orbital radiotherapy for graves’ ophthalmopathy. Ophthalmology 2002, 109(11):2100-2107.
• [25]Mourits MP, van Kempen-Harteveld ML, Garcia MB, et al.: Radiotherapy for graves’ orbitopathy: randomized placebo-controlled study. Lancet 2000, 355(9214):1505-1509.
• [26]Marquez SD, Lum BL, McDougall IR, et al.: Long-term results of irradiation for patients with progressive graves’ ophthalmopathy. Int J Radiat Oncol Biol Phys 2001, 51(3):766-774.
• [27]Prummel MF, Terwee CB, Gerding MN, et al.: A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild graves’ ophthalmopathy. J Clin Endocrinol Metab 2004, 89(1):15-20.
• [28]Wakelkamp IM, Tan H, Saeed P, et al.: Orbital irradiation for graves’ disease. Is it safe? a long-term follow-up study. Ophthalmology 2004, 111(8):1557-1562.
• [29]Akmansu M, Dirican B, Bora H, et al.: The risk of radiation-induced carcinogenesis after external beam radiotherapy of graves’ orbitopathy. Ophthalmic Res 2003, 35:150-153.
• [30]Kahaly GJ, Rosler H, Pitz S, et al.: Low- versus high-dose radiotherapy for graves’ ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab 2000, 85(1):102-108.
• [31]Gerling J, Kommerell G, Henne K, et al.: Retrobular irradiation for thyroid-associated orbitopathy-double blind comparison between 2.4 and 16Gy. Int J Radiat Oncol Biol Phys 2003, 55(1):582-589.